Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

AACR 2023 highlights on advances in the treatment of resected high-risk melanoma with Jeffrey Weber

Reporting from AACR 2023, Jeffrey S. Weber presents the results from primary analysis of the KEYNOTE-942 trial, testing a combination of pembrolizumab plus a novel mRNA-based vaccine based on personalised neoantigens from patients with high-risk resected melanoma, compared to pembrolizumab alone. The combined therapy showed an encouraging 44% reduction in the risk of recurrence or death. It’s the first successful cancer vaccine trial in melanoma but a larger confirmatory study is needed.

Abstract: CT001 - A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.